# US 2013/0281383 A1 · Novel uses of elafin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281383 A1
- Document ID: US20130281383A1
- Status: Published application
- Kind: A1
- Application number: 13/582,738
- Filed: 2011-03-02
- Published: 2013-10-24
- Earliest claimed: 2010-03-03
- Assignees: Proteo Biotech AG
- Inventors: Oliver Wiedow; Birge Bargmann; Barbara Kahlke; Lee Shaw; Nils Wichmann
- Web page: https://patentgrep.com/patent/US20130281383A1

## CPC

- C07K 14/47: from mammals
- A61K 38/1709: {from mammals}
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- C07K 14/8121: {Serpins}
- C12N 9/6448: {Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}
- C12Y 304/21037: Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to novel uses of the polypeptide elafin, and/or homologies, derivatives or fragments thereof having inhibitory activity against leukocyte elastase for the prevention and treatment of medical conditions like SIRS.

## Claims

### Claim 1

A polypeptide comprising the sequence of SEQ ID NO: 1 or homologues, derivatives, or fragments thereof having inhibitory activity against leukocyte elastase.

### Claim 2 (depends on 1)

A wound dressing, comprising polypeptide according to claim 1.

### Claim 3 (depends on 1)

An organ-perfusion medium, comprising the polypeptide according to claim 1.

### Claim 4 (depends on 11)

The method according to claim 11, wherein the polypeptide is administered intravenously.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the dosage is between 10 and 600 mg per day and/or per unit-dosage.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the administration is an intravenous bolus of 100 mg to 400 mg.

### Claim 7 (depends on 11)

The method according to claim 11, wherein the polypeptide is administered subcutaneously.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the dosage is between 10 and 600 mg per day and/or per unit-dosage.

### Claim 9 (depends on 11)

The method according to claim 11, wherein the administering is carried out before, during or shortly after surgery.

### Claim 10 (depends on 11)

The method according to claim 11, wherein the polypeptide is administered not more than twice.

### Claim 11 (depends on 1)

A method for the prevention of one or more inflammatory diseases, comprising administering the polypeptide of claim 1 to a subject.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the one or more inflammatory diseases is systemic inflammation response syndrome (SIRS) and/or multiple-organ dysfunction syndrome (MODS).

### Claim 13 (depends on 4)

The method according to claim 4, wherein the administration is an intravenous bolus of about 200 mg.

### Claim 14 (depends on 7)

The method according to claim 7, wherein the administration is a subcutaneous bolus of 50 mg to 200 mg.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the administration is a subcutaneous bolus of about 100 mg.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the polypeptide is administered not more than once.

### Claim 17 (depends on 1)

A composition, comprising the polypeptide according to claim 1 and a pharmaceutically acceptable diluent or carrier.
